Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of United Therapeutics Corporation (NASDAQ: UTHR) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of United Therapeutics Corporation (NASDAQ: UTHR)  concerning whether a series of statements by United Therapeutics Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 27, 2017, United Therapeutics revealed that it recorded a $210 million accrual relating to a potential settlement in connection with a U.S. Department of Justice investigation of United Therapeutics concerning possible violations of the Federal Anti-Kickback Statute and the Federal False Claims Act.

Following this news, NASDAQ: UTHR fell sharply during intraday trading on July 27, 2017, damaging investors.

Based in Silver Spring, Maryland, and founded in 1996 United Therapeutics Corporation a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases.

If you purchased shares of United Therapeutics Corporation (NASDAQ: UTHR) on or before July 27, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185